An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men

NCT ID: NCT02292342

Last Updated: 2016-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-31

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim: To investigate the dose-dependent vascular effect (primarily using FMD) of 3 low-level doses of pure (-)-epicatechin ≤ 1 mg/kg BW (0.1, 0.5 \& 1.0 mg/kg BW) in healthy men.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vasodilation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Flow mediated dilatation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

0.1 mg/ kg BW pure (-)-epicatechin

0.1 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Group Type ACTIVE_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

Control

Epicatechin 0.1 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.1 mg/kg

Epicatechin 0.5 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.5

Epicatechin 1.0 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 1.0

0.5 mg/ kg BW pure (-)-epicatechin

0.5 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Group Type ACTIVE_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

Control

Epicatechin 0.1 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.1 mg/kg

Epicatechin 0.5 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.5

Epicatechin 1.0 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 1.0

1.0 mg/ kg BW pure (-)-epicatechin

1.0 mg/ kg BW pure (-)-epicatechin (according to volunteer) dissolved in 3 ml/kg BW of water.

Group Type ACTIVE_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

Control

Epicatechin 0.1 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.1 mg/kg

Epicatechin 0.5 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.5

Epicatechin 1.0 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 1.0

0.0 mg/ kg BW pure (-)-epicatechin

Water only (3 ml/kg BW)

Group Type PLACEBO_COMPARATOR

Water

Intervention Type DIETARY_SUPPLEMENT

Control

Epicatechin 0.1 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.1 mg/kg

Epicatechin 0.5 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 0.5

Epicatechin 1.0 mg/kg

Intervention Type DIETARY_SUPPLEMENT

EC 1.0

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Water

Control

Intervention Type DIETARY_SUPPLEMENT

Epicatechin 0.1 mg/kg

EC 0.1 mg/kg

Intervention Type DIETARY_SUPPLEMENT

Epicatechin 0.5 mg/kg

EC 0.5

Intervention Type DIETARY_SUPPLEMENT

Epicatechin 1.0 mg/kg

EC 1.0

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body Mass Index 20-27.5 kg/m2
* Normal blood pressure at screening (\< 150/90)
* Non-smoker
* Non-vegetarian
* 'Normal - low' chocolate consumer (\<2 potions per week)
* 'Normal - low' coffee/ tea drinker (\<3 cups per day)
* Regular exercise routine
* Signed consent form

Exclusion Criteria

* Haemoglobin (anaemia marker) \< 125 g/l
* Gamma GT (liver enzymes) \> 80 IU/l
* Cholesterol \> 6.5 mmol/l
* Suffered a myocardial infarction or stroke in the last 12 months
* Suffers from any cardiovascular or metabolic disorders (e.g. diabetes or any other endocrine or liver diseases)
* Suffers from any blood-clotting disorder, and/or takes supporting medication
* Any dietary restrictions or on a weight reducing diet
* On any lipid-modifying or blood pressure lowering medication
* Consuming any specific vitamin/ herbal supplements or fish oils
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Reading

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jeremy Paul Edward Spencer

Professor Jeremy P.E. Spencer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jeremy Spencer, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Reading

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Food and Nutritional Sciences

Reading, Berkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EpicatechinStudy

Identifier Type: -

Identifier Source: org_study_id